Humana Challenges UnitedHealthcare’s Medicare Advantage Leadership

Humana is positioning itself to become the dominant force in the Medicare Advantage market, projecting membership growth that could dethrone long-time industry leader UnitedHealthcare. However, this aggressive expansion strategy comes with significant financial risks as the company navigates rising medical costs and declining quality ratings in an increasingly challenging healthcare landscape.

Explosive Medicare Advantage Membership Growth

Humana delivered impressive enrollment results during the 2026 sign-up period, adding approximately 1 million individual Medicare Advantage members. Company executives project this momentum will continue throughout the year, potentially bringing total MA membership to nearly 7.3 million by year-end—a substantial increase from 5.8 million members at the conclusion of 2025.

This represents more than 25% membership growth in a single year, positioning Humana as an aggressive outlier in a market where most major carriers are deliberately contracting their member bases. The company’s expansion strategy stands in stark contrast to industry trends, where insurers have been cutting benefits and exiting markets to improve profit margins amid mounting cost pressures.

UnitedHealthcare’s Market Position Under Pressure

UnitedHealthcare, the long-standing Medicare Advantage market leader, expects to lose over 1.1 million MA members during 2026 as part of its own margin recovery initiatives. This strategic reduction could shrink UnitedHealthcare’s MA membership to between 7.2 million and 7.3 million enrollees—putting the two insurance giants in a virtual tie for market leadership.

The competitive dynamics reflect fundamentally different strategic approaches. While UnitedHealthcare prioritizes profitability through controlled contraction, Humana has chosen to maintain benefit generosity in its remaining markets despite reducing its geographic footprint. This decision has made Humana an attractive option for Medicare beneficiaries seeking comprehensive coverage, though it raises questions about long-term financial sustainability.

Profitability Concerns Amid Rapid Expansion

During a Wednesday investor call discussing fourth quarter results, Humana executives acknowledged investor concerns about the financial implications of such substantial membership growth. The company maintains that new enrollees will prove profitable on average, citing several favorable factors supporting this outlook.

First, the majority of new members enrolled in highly rated Humana plans that qualify for more lucrative quality bonus payments from the Centers for Medicare & Medicaid Services (CMS). Second, most new members transferred from existing Medicare plans rather than joining the program for the first time—a demographic profile that typically demonstrates better cost economics. Finally, approximately one-third of new enrollees were previous Humana members, giving the Louisville, Kentucky-based insurer valuable historical data on their health status and expected medical needs.

“We continue to feel good about our membership growth,” affirmed Humana CEO Jim Rechtin during the investor call, expressing confidence in the company’s expansion strategy.

Financial Results Reveal Underlying Challenges

Despite leadership’s optimistic outlook, Humana’s fourth quarter financial performance suggests concerning trends. The company posted a substantial $796 million loss for the quarter, exceeding the $693 million loss recorded in Q4 2024 when unexpectedly high medical spending caught the insurer off guard.

The company’s medical loss ratio (MLR)—a critical metric measuring the percentage of premium revenue spent on patient care—reached 93.1% in the quarter, increasing one percentage point year-over-year. This elevated MLR indicates that Humana is dedicating a larger share of premium income to medical costs, leaving less for administrative expenses, marketing, and profit retention. Insurers typically aim to maintain lower MLRs while staying within regulatory compliance thresholds to avoid penalties.

Conservative 2026 Earnings Guidance

Humana issued 2026 earnings guidance that fell significantly short of investor expectations, projecting adjusted earnings per share of approximately $9 compared to analyst consensus estimates of around $12. This disappointing outlook mirrors similar warnings from managed care competitors including UnitedHealth, CVS Health, and Elevance Health. Humana’s stock price dropped 4% in morning trading Wednesday following the results announcement.

The reduced guidance stems primarily from Humana’s declining star ratings, which will negatively impact quality bonus payments from CMS during 2026. Chief Financial Officer Celeste Mellet noted the guidance reflects unusual conservatism given the substantial challenges facing the health insurance industry, including escalating costs for hospital services and prescription drugs combined with inadequate reimbursement rate increases in federal programs.

Strategic Initiatives and Future Growth

Despite Medicare Advantage headwinds, Humana continues investing in complementary business segments. The company plans to expand its Medicaid division and add 60 to 70 new CenterWell primary care locations during 2026. CEO Rechtin teased potential merger and acquisition activity in the primary care sector, stating, “We also hope to soon announce a strategic acquisition in the primary care space.”

Humana maintains it remains on track to double pre-tax margins in its privatized Medicare plans during 2026 compared to 2025, excluding star rating impacts. However, including the star rating effect, the company expects MA margins to finish slightly below breakeven for the year—a sobering acknowledgment of the program’s profitability challenges.